Ultrasound Measurement of Vascular Density to Evaluate Response to Anti-Angiogenic Therapy in Renal Cell Carcinoma
暂无分享,去创建一个
Paul A. Dayton | Virginie Papadopoulou | Stephen Aylward | W. Kimryn Rathmell | Juan D. Rojas | Tomasz J. Czernuszewicz | Rajalekha M. Rajamahendiran | Anna Chytil | Yun-Chen Chiang | Diana C. Chong | Victoria L. Bautch | Ryan C. Gessner | W. Rathmell | S. Aylward | P. Dayton | R. Gessner | V. Bautch | J. Rojas | Rajalekha M Rajamahendiran | V. Papadopoulou | Yun-Chen J Chiang | A. Chytil
[1] Vicky Goh,et al. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies , 2010, Cancer biology & therapy.
[2] Keith Flaherty,et al. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. , 2008, Urologic oncology.
[3] Paul A. Dayton,et al. Early Assessment of Tumor Response to Radiation Therapy using High-Resolution Quantitative Microvascular Ultrasound Imaging , 2018, Theranostics.
[4] Haesun Choi,et al. We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Michael D. Abràmoff,et al. Image processing with ImageJ , 2004 .
[6] Mukund Seshadri,et al. Dll4 Blockade Potentiates the Anti-Tumor Effects of VEGF Inhibition in Renal Cell Carcinoma Patient-Derived Xenografts , 2014, PloS one.
[7] François Tranquart,et al. Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection. , 2015, Radiology.
[8] J. Knox,et al. Sunitinib in solid tumors , 2009, Expert opinion on investigational drugs.
[9] Gabriele Bergers,et al. Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.
[10] Fabio Cominelli,et al. Targeting mucosal addressin cellular adhesion molecule (MAdCAM)-1 to noninvasively image experimental Crohn's disease. , 2006, Gastroenterology.
[11] Michael B Atkins,et al. Resistance to targeted therapy in renal-cell carcinoma. , 2009, The Lancet. Oncology.
[12] Gavin Thurston,et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis , 2006, Nature.
[13] B. Ariff,et al. The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteria , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[14] Paul A. Dayton,et al. 3-D Ultrasound Localization Microscopy for Identifying Microvascular Morphology Features of Tumor Angiogenesis at a Resolution Beyond the Diffraction Limit of Conventional Ultrasound , 2017, Theranostics.
[15] Holger Gerhardt,et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis , 2007, Nature.
[16] Paul A. Dayton,et al. Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy , 2018, Theranostics.
[17] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[18] Sanjiv S Gambhir,et al. Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] K. Cox,et al. Contrast-Enhanced Ultrasound Biopsy of Sentinel Lymph Nodes in Patients with Breast Cancer: Implications for Axillary Metastases and Conservation , 2015, Annals of Surgical Oncology.
[20] Paul A Dayton,et al. Quantification of Microvascular Tortuosity during Tumor Evolution Using Acoustic Angiography. , 2015, Ultrasound in medicine & biology.
[21] Haesun Choi,et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Dimitre Hristov,et al. VEGFR2-Targeted Three-Dimensional Ultrasound Imaging Can Predict Responses to Antiangiogenic Therapy in Preclinical Models of Colon Cancer. , 2016, Cancer research.
[23] Dimitre Hristov,et al. Three-Dimensional Ultrasound Molecular Imaging of Angiogenesis in Colon Cancer Using a Clinical Matrix Array Ultrasound Transducer , 2015, Investigative radiology.
[24] F. Stuart Foster,et al. High Resolution Ultrasound Superharmonic Perfusion Imaging: In Vivo Feasibility and Quantification of Dynamic Contrast-Enhanced Acoustic Angiography , 2017, Annals of Biomedical Engineering.
[25] Fabian Kiessling,et al. Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects. , 2016, Radiology.
[26] Kristina M. Cook,et al. Angiogenesis Inhibitors: Current Strategies and Future Prospects , 2010, CA: a cancer journal for clinicians.
[27] Paul A Dayton,et al. Validation of dynamic contrast-enhanced ultrasound in rodent kidneys as an absolute quantitative method for measuring blood perfusion. , 2011, Ultrasound in medicine & biology.
[28] Paul A Dayton,et al. Quantitative Volumetric Perfusion Mapping of the Microvasculature Using Contrast Ultrasound , 2010, Investigative radiology.
[29] Charles M. Perou. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013 .
[30] Wolfgang A Weber,et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Dimitre Hristov,et al. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer. , 2017, Radiology.
[32] François Tranquart,et al. First-in-Human Ultrasound Molecular Imaging With a VEGFR2-Specific Ultrasound Molecular Contrast Agent (BR55) in Prostate Cancer: A Safety and Feasibility Pilot Study , 2017, Investigative radiology.
[33] M. Tanter,et al. Ultrafast ultrasound localization microscopy for deep super-resolution vascular imaging , 2015, Nature.
[34] Michael B Lawrence,et al. Ultrasound-based molecular imaging and specific gene delivery to mesenteric vasculature by endothelial adhesion molecule targeted microbubbles in a mouse model of Crohn's disease. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[35] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[36] Minhong Yan,et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis , 2006, Nature.
[37] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[38] Xin Huang,et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] R. Figlin,et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Molly L Flexman,et al. Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy. , 2012, Ultrasound in medicine & biology.
[41] Ingrid Leguerney,et al. Molecular ultrasound imaging using contrast agents targeting endoglin, vascular endothelial growth factor receptor 2 and integrin. , 2015, Ultrasound in medicine & biology.
[42] F. Stuart Foster,et al. Acoustic Angiography: A New Imaging Modality for Assessing Microvasculature Architecture , 2013, Int. J. Biomed. Imaging.
[43] Linda Chami,et al. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results. , 2011, Radiology.
[44] The Cancer Genome Atlas Research Network. COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.
[45] Paul A Dayton,et al. A Pilot Clinical Study in Characterization of Malignant Renal-cell Carcinoma Subtype with Contrast-enhanced Ultrasound , 2017, Ultrasonic imaging.
[46] John C Chappell,et al. Regulation of blood vessel sprouting. , 2011, Seminars in cell & developmental biology.
[47] Nathalie Lassau,et al. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results. , 2013, European journal of radiology.
[48] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[49] W. Kaelin,et al. Molecular pathways in renal cell carcinoma--rationale for targeted treatment. , 2006, Seminars in oncology.
[50] Dimitre Hristov,et al. Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging , 2017, Angiogenesis.
[51] John C Chappell,et al. Flt-1 (Vascular Endothelial Growth Factor Receptor-1) Is Essential for the Vascular Endothelial Growth Factor–Notch Feedback Loop During Angiogenesis , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[52] J Nuyts,et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). , 2003, European journal of cancer.
[53] Martijn R. Meijerink,et al. Targeted therapies in renal cell cancer: recent developments in imaging , 2010, Targeted Oncology.
[54] Paul A Dayton,et al. A new preclinical ultrasound platform for widefield 3D imaging of rodents. , 2018, The Review of scientific instruments.
[55] Mickael Tanter,et al. Resolution limits of ultrafast ultrasound localization microscopy , 2015, Physics in medicine and biology.
[56] Gavin Thurston,et al. Dll4-Notch signaling as a therapeutic target in tumor angiogenesis , 2011, Vascular cell.
[57] Jonathan R Lindner,et al. Quantitative assessment of placental perfusion by contrast-enhanced ultrasound in macaques and human subjects. , 2016, American journal of obstetrics and gynecology.
[58] Fabian Kiessling,et al. Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38) , 2011, European Radiology.
[59] J. Yeh,et al. A Comparative Evaluation of Ultrasound Molecular Imaging, Perfusion Imaging, and Volume Measurements in Evaluating Response to Therapy in Patient-Derived Xenografts , 2013, Technology in cancer research & treatment.
[60] Linda Chami,et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. , 2006, European journal of cancer.
[61] Maximilian Reiser,et al. Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation , 2017, PloS one.
[62] F. Stuart Foster,et al. Microultrasound Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 in a Mouse Model of Tumor Angiogenesis , 2007, Molecular imaging.